Singapore S*BIO Inks "One Of The Biggest" Biotech Deals in Asia With Onyx For JAK2 Inhibitors
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Singapore-based S*BIO inked a development collaboration and option and license agreement with Onyx Pharmaceuticals for S*BIO's two JAK2 inhibitors SB1518 and SB1578, S*BIO announced Jan. 6
You may also be interested in...
CTI Lands Baxter As Pacritinib Partner To Try To Reach Finish Line
The beleaguered oncology company has inked a partnership for its third late-stage candidate with hopes of taking it through approval, unlike its last two attempts.
Singapore’s S*BIO Finds Ideal Partner In CTI For Its JAK2 Inhibitor Abandoned By Onyx
Cell Therapeutics licenses Phase III pacritinib from Singapore’s S*BIO about a year after Onyx declined an option on the myelofibrosis candidate.
CTI Sees Ideal Pipeline Acquisition In JAK2 Inhibitor Abandoned By Onyx
Cell Therapeutics licenses Phase III pacritinib from Singapore’s S*BIO about a year after Onyx declined an option on the myelofibrosis candidate.